High-dose cyclophosphamide for graft-versus-host disease prevention.
about
Haploidentical Stem Cell Transplantation in Adult Haematological MalignanciesMarrow-Infiltrating Lymphocytes - Role in Biology and Cancer TherapyExploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer ImmunotherapyCD8+ tumor-infiltrating T cells are trapped in the tumor-dendritic cell network.HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation.Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphomaThe allure and peril of hematopoietic stem cell transplantation: overcoming immune challenges to improve success.Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis.Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: a meta-analysis based on time-to-event data from randomized controlled trials.Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamideNovel regulatory therapies for prevention of Graft-versus-host disease.Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of β-thalassemia and sickle cell disease.Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamideComparison of Three Distinct Prophylactic Agents Against Invasive Fungal Infections in Patients Undergoing Haplo-identical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide.Selective Treg reconstitution during lymphopenia normalizes DC costimulation and prevents graft-versus-host disease.Hematopoietic stem cell transplantation for chronic lymphocytic leukemia.HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease.Sirolimus and post transplant Cy synergistically maintain mixed chimerism in a mismatched murine model.Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β(A(T87Q))-Globin Gene.Mouse models in bone marrow transplantation and adoptive cellular therapy.Antigen and lymphopenia-driven donor T cells are differentially diminished by post-transplantation administration of cyclophosphamide after hematopoietic cell transplantation.Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia.Optimizing management of myelodysplastic syndromes post-allogeneic transplantation.The expanding frontier of hematopoietic cell transplantation.Experts' considerations on HLA-haploidentical stem cell transplantation.Recent advances in hematopoietic stem cell transplantation.Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis.Human leukocyte antigen-haploidentical hematopoietic stem cell transplant for a patient with histiocytic sarcoma.Donor-lymphocyte infusion following haploidentical hematopoietic cell transplantation with peripheral blood stem cell grafts and PTCy.Unrelated cord blood compared with haploidentical grafts in patients with hematological malignancies.Stability of Chimerism in Non-Obese Diabetic Mice Achieved By Rapid T Cell Depletion Is Associated With High Levels of Donor Cells Very Early After Transplant.
P2860
Q26745527-5A8525FC-4903-45A5-A25B-1915C5C3AA16Q26749560-15D8C7CF-9C92-4EE6-B3D3-A6C47DEB3DD0Q26779184-BE0D5CC1-D083-4AD5-B1C4-A20FCB876A91Q30533257-FABE75E6-3582-4AA7-8897-4F202F27C2FCQ33566388-69355D64-51D6-41B1-943F-40B0B958CC37Q33608520-1210276F-2FDC-463C-9A61-8F23758B2330Q33724352-22B2C7DA-047D-47A0-87A9-31D14C733F30Q33732489-3D81F481-71EC-41CF-8C06-FB98745375FFQ33971524-B28A2C59-ADC3-4EC2-9109-1CB49605C5EBQ34138598-FE0BEB9E-FDE7-4C82-98A7-B0420D67269BQ34269481-0E1C850D-E244-4EF2-B05B-A93BA8A1EEF8Q34293038-1DEAE4AB-2030-46D2-9B24-2AF48A3E4C8AQ34449867-E76C106A-D4A0-49EC-9C5E-7030C7CF5FB9Q35505839-69345DA2-581B-48DA-AFC1-A917A9F07886Q36028504-445866A8-DE5D-4EEB-8469-81228464D6A2Q36105996-0CA18DF0-F45C-40D7-AFE2-3FA5F3E3E9E5Q36416452-A0D8DFBE-C72A-40F9-BC86-F8E0EC05AF8DQ36425417-05D0BB97-99EB-45B1-BDA0-EA61DA17B795Q36433025-209DD94F-90C3-4372-89CF-5A6440069F1FQ36654528-B156A34C-F916-4BAE-86ED-66AF2D0C7456Q37677563-07F4C0AA-93F8-487F-AFF8-91C299DF292BQ37721898-CFABF249-5338-4570-8F8E-59F4B346C786Q37730037-C12A55B1-F2C3-4FBC-B03F-3EF899306569Q37955235-FA6183B1-1772-4634-A959-E3ACA8C89E4BQ38032255-DEFF6771-BF0E-4CA7-BA3B-F268BAE2F1A1Q38198728-2E526F26-D85C-469C-BCA8-523594137565Q39405882-9CF2AB86-64F2-401F-AF7E-81BA7B6399FCQ41484569-AEBE39F5-CE4C-465F-8758-178B70899B1DQ42721532-05F7F610-51A5-4ECC-8FE6-2A8B22845713Q48182017-A877D4C4-6AC7-43F2-87A1-263D24388A1AQ50588099-521FD9D0-3625-4347-8C7F-67DAE1275AC2Q53824120-32BAFC21-34AF-4847-BA2C-809495A8527F
P2860
High-dose cyclophosphamide for graft-versus-host disease prevention.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
High-dose cyclophosphamide for graft-versus-host disease prevention.
@ast
High-dose cyclophosphamide for graft-versus-host disease prevention.
@en
type
label
High-dose cyclophosphamide for graft-versus-host disease prevention.
@ast
High-dose cyclophosphamide for graft-versus-host disease prevention.
@en
prefLabel
High-dose cyclophosphamide for graft-versus-host disease prevention.
@ast
High-dose cyclophosphamide for graft-versus-host disease prevention.
@en
P2093
P2860
P1476
High-dose cyclophosphamide for graft-versus-host disease prevention.
@en
P2093
Ephraim J Fuchs
Leo Luznik
Richard J Jones
P2860
P304
P356
10.1097/MOH.0B013E32833EAF1B
P577
2010-11-01T00:00:00Z